Table 5.

Longitudinal change of comprehensive MRI measurements and clinical outcomes for three dose groups during the trial

Measurement	Group	Base time	48 weeks	P value
T1rho (ms)	High	41.55 ± 2.86	38.82 ± 2.11	0.002*
	Mid	39.30 ± 2.01	37.48 ± 1.93	0.002*
	Low	38.91 ± 3.24	37.94 ± 3.13	0.038*
T2 (ms)	High	42.12 ± 4.13	39.65 ± 3.37	0.003*
	Mid	40.16 ± 2.60	37.21 ± 1.73	0.003*
	Low	43.77 ± 6.09	39.73 ± 2.78	0.075
T2star (ms)	High	23.43 ± 2.30	21.77 ± 1.41	0.011*
	Mid	24.22 ± 2.18	22.60 ± 1.77	0.012*
	Low	25.11 ± 2.32	23.09 ± 1.27	0.012*
R2star (s−1)	High	48.47 ± 4.69	51.25 ± 2.85	0.021*
	Mid	44.57 ± 8.26	46.80 ± 10.57	0.180
	Low	45.21 ± 3.16	48.57 ± 2.29	0.005*
ADC (×10−3 mm2/s)	High	1.53 ± 0.10	1.37 ± 0.08	0.026*
	Mid	1.59 ± 0.15	1.52 ± 0.11	0.112
	Low	1.56 ± 0.12	1.42 ± 0.14	0.052
FA	High	0.47 ± 0.04	0.51 ± 0.05	0.05
	Mid	0.45 ± 0.06	0.47 ± 0.04	0.225
	Low	0.47 ± 0.02	0.51 ± 0.03	0.075
WORMS	High	10.88 ± 5.45	11.04 ± 5.02	0.918
	Mid	12.42 ± 7.16	12.38 ± 7.17	0.985
	Low	14.43 ± 7.06	15.10 ± 6.90	0.758
CV	High	27,863.12 ± 5688.74	28,073.37 ± 5871.8	0.599
	Mid	34,645.82 ± 4666.97	34,870.24 ± 4991.32	0.758
	Low	31,815.91 ± 4879.96	31,607.52 ± 5238.41	0.514
WOMAC	High	38.83 ± 12.61	24.33 ± 12.88	0.077
	Mid	48.83 ± 16.22	23.17 ± 12.89	0.035*
	Low	46.17 ± 21.48	27.50 ± 18.64	0.139
SF-36	High	88.83 ± 14.41	74.0 ± 15.74	0.119
	Mid	89.67 ± 10.21	70.5 ± 8.41	0.005*
	Low	91.0 ± 13.80	71.5 ± 14.88	0.040*

Values are given as mean ± standard deviation of the mean

*Significantly different between two groups (P < 0.05)